Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Eptacog Beta→

Eptacog Beta Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1851951-40-0
Molecular formula
C2077H3172N582O629S31
Molecular weight
~50000 g/mol
Drug class
Recombinant activated human coagulation factor VIIa (rFVIIabypassing haemostatic agent)
Mechanism of action
Activated factor VII promotes haemostasis by binding tissue factor and activating factor X, increasing thrombin generation and fibrin formation through a pathway that can bypass deficient or inhibited factor VIII or IX.
Indications / reported uses
  • Treatment of bleeding episodes and prevention of bleeding during surgery or invasive procedures in adults and adolescents aged 12 years or older with congenital haemophilia and inhibitors to factor VIII or IX, or expected poor response to factor replacement, under the Cevenfacta authorisation

Sources: EMA Cevenfacta EPAR · EMA overview · US FDA Sevenfact page

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Eptacog Beta Environmental Risk Assessment (ERA) (the Eptacog Beta ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.